collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid arthritis

shared collection
111 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28399940/baseline-jak-phosphorylation-profile-of-peripheral-blood-leukocytes-studied-by-whole-blood-phosphospecific-flow-cytometry-is-associated-with-1-year-treatment-response-in-early-rheumatoid-arthritis
#1
Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Hannu Kautiainen, Heikki Repo, Marjatta Leirisalo-Repo
BACKGROUND: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in peripheral blood CD4(+) T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA. METHODS: Thirty-five DMARD-naïve patients with early RA provided blood samples for whole blood flow cytometric determination of phosphorylation of JAKs in CD4(+) and CD8(+) T cells, CD19(+) B cells, and CD14(+) monocytes...
April 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28598787/severe-adverse-drug-reactions-to-biological-disease-modifying-anti-rheumatic-drugs-in-elderly-patients-with-rheumatoid-arthritis-in-clinical-practice
#2
Leticia Leon, Alejandro Gomez, Cristina Vadillo, Esperanza Pato, Luis Rodriguez-Rodriguez, Juan Angel Jover, Lydia Abasolo
OBJECTIVES: Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. METHODS: A 14-year retrospective longitudinal study was performed...
June 6, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28473424/glucocorticoids-in-rheumatoid-arthritis-the-picture-is-shaping-up
#3
EDITORIAL
Frank Buttgereit, Johannes W Bijlsma
No abstract text is available yet for this article.
May 4, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28215362/efficacy-and-safety-of-sirukumab-in-patients-with-active-rheumatoid-arthritis-refractory-to-anti-tnf-therapy-sirround-t-a-randomised-double-blind-placebo-controlled-parallel-group-multinational-phase-3-study
#4
Daniel Aletaha, Clifton O Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P Tak, Sharon Popik
BACKGROUND: Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under development for the treatment of rheumatoid arthritis and other diseases. We aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T). METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre study at 183 hospitals and private rheumatology clinics in 20 countries (Argentina, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, UK, and USA)...
March 25, 2017: Lancet
https://www.readbyqxmd.com/read/28356243/efficacy-of-glucocorticoids-conventional-and-targeted-synthetic-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#5
Katerina Chatzidionysiou, Sharzad Emamikia, Jackie Nam, Sofia Ramiro, Josef Smolen, Désirée van der Heijde, Maxime Dougados, Johannes Bijlsma, Gerd Burmester, Marieke Scholte, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To perform a systematic literature review (SLR) informing the 2016 update of the recommendations for the management of rheumatoid arthritis (RA). METHODS: An SLR for the period between 2013 and 2016 was undertaken to assess the efficacy of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) (tofacitinib and baricitinib) in randomised clinical trials. RESULTS: For GCs, four studies were included in the SLR...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#6
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#7
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28367663/three-out-of-four-disease-modifying-anti-rheumatic-drug-na%C3%A3-ve-rheumatoid-arthritis-patients-meet-28-joint-disease-activity-score-remission-at-12%C3%A2-months-results-from-the-fin-era-cohort
#8
T Rannio, J Asikainen, P Hannonen, T Yli-Kerttula, P Ekman, L Pirilä, L Kuusalo, M Mali, M Puurtinen-Vilkki, S Kortelainen, J Paltta, K Taimen, M Kauppi, K Laiho, S Nyrhinen, H Mäkinen, P Isomäki, T Uotila, K Aaltonen, H Kautiainen, T Sokka
OBJECTIVE: To assess what proportion of patients with disease-modifying anti-rheumatic drug (DMARD)-naïve early rheumatoid arthritis (ERA) reach 28-joint Disease Activity Score (DAS28) remission over 1 year, and remission variability across clinics in Finland. METHOD: Patients with DMARD-naïve newly diagnosed inflammatory arthritis were recruited. The proportion of patients in 28-joint Disease Activity Score with three variables (DAS28-3) remission was compared across sites...
April 3, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/23104761/smoking-and-overweight-determine-the-likelihood-of-developing-rheumatoid-arthritis
#9
MULTICENTER STUDY
Maria J H de Hair, Robert B M Landewé, Marleen G H van de Sande, Dirkjan van Schaardenburg, Lisa G M van Baarsen, Danielle M Gerlag, Paul P Tak
OBJECTIVES: Rheumatoid arthritis (RA) is a prototypic chronic inflammatory disease with a debilitating course if untreated. A genetic predisposition for RA is known, and its occurrence is associated with the presence of autoantibodies in the serum and with environmental factors. It is unknown if smoking and overweight are contributory factors for developing RA in individuals with RA-specific autoantibodies in the serum. METHODS: Fifty-five individuals at risk for developing RA, based on the presence of RA-specific autoantibodies in the serum, who never had any evidence of arthritis upon physical examination, were followed over time...
October 2013: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/24934191/defining-populations-at-risk-of-rheumatoid-arthritis-the-first-steps-to-prevention
#10
REVIEW
Laura Hunt, Paul Emery
Preventing disease is a public health priority. In recent years, this focus has evolved to include noncommunicable chronic diseases such as cardiovascular disease and diabetes mellitus but is novel in rheumatic diseases such as rheumatoid arthritis (RA). In order to prevent RA, the 'at-risk' populations need to be defined. To date, a number of studies have attempted to clarify our understanding of these cohorts and how they could be identified. Suggested terminology has now been published to define individuals who might go on to develop RA...
September 2014: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/25892196/shared-epitope-antagonistic-ligands-a-new-therapeutic-strategy-in-mice-with-erosive-arthritis
#11
Song Ling, Ying Liu, Jiaqi Fu, Alessandro Colletta, Chaim Gilon, Joseph Holoshitz
OBJECTIVE: The mechanisms underlying bone damage in rheumatoid arthritis (RA) are incompletely understood. We recently identified the shared epitope (SE), an HLA-DRB1-coded 5-amino acid sequence motif carried by the majority of RA patients as a signal transduction ligand that interacts with cell surface calreticulin and accelerates osteoclast (OC)-mediated bone damage in collagen-induced arthritis (CIA). Given the role of the SE/calreticulin pathway in arthritis-associated bone damage, we sought to determine the therapeutic targetability of calreticulin...
May 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#12
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27991858/eular-definition-of-arthralgia-suspicious-for-progression-to-rheumatoid-arthritis
#13
MULTICENTER STUDY
Hanna W van Steenbergen, Daniel Aletaha, Liesbeth J J Beaart-van de Voorde, Elisabeth Brouwer, Catalin Codreanu, Bernard Combe, João E Fonseca, Merete L Hetland, Frances Humby, Tore K Kvien, Karin Niedermann, Laura Nuño, Sue Oliver, Solbritt Rantapää-Dahlqvist, Karim Raza, Dirkjan van Schaardenburg, Georg Schett, Liesbeth De Smet, Gabriella Szücs, Jirí Vencovský, Piotr Wiland, Maarten de Wit, Robert L Landewé, Annette H M van der Helm-van Mil
BACKGROUND: During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience. METHODS: The taskforce consisted of 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and 1 research fellow...
March 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27697765/eular-recommendations-for-cardiovascular-disease-risk-management-in-patients-with-rheumatoid-arthritis-and-other-forms-of-inflammatory-joint-disorders-2015-2016-update
#14
REVIEW
R Agca, S C Heslinga, S Rollefstad, M Heslinga, I B McInnes, M J L Peters, T K Kvien, M Dougados, H Radner, F Atzeni, J Primdahl, A Södergren, S Wallberg Jonsson, J van Rompay, C Zabalan, T R Pedersen, L Jacobsson, K de Vlam, M A Gonzalez-Gay, A G Semb, G D Kitas, Y M Smulders, Z Szekanecz, N Sattar, D P M Symmons, M T Nurmohamed
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base...
January 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27784339/bone-loss-and-aggravated-autoimmune-arthritis-in-hla-dr%C3%AE-1-bearing-humanized-mice-following-oral-challenge-with-porphyromonas-gingivalis
#15
Indra Sandal, Anastasios Karydis, Jiwen Luo, Amanda Prislovsky, Karen B Whittington, Edward F Rosloniec, Chen Dong, Deborah V Novack, Piotr Mydel, Song Guo Zheng, Marko Z Radic, David D Brand
BACKGROUND: The linkage between periodontal disease and rheumatoid arthritis is well established. Commonalities among the two are that both are chronic inflammatory diseases characterized by bone loss, an association with the shared epitope susceptibility allele, and anti-citrullinated protein antibodies. METHODS: To explore immune mechanisms that may connect the two seemingly disparate disorders, we measured host immune responses including T-cell phenotype and anti-citrullinated protein antibody production in human leukocyte antigen (HLA)-DR1 humanized C57BL/6 mice following exposure to the Gram-negative anaerobic periodontal disease pathogen Porphyromonas gingivalis...
October 26, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27799159/patient-reported-outcomes-from-a-randomised-phase-iii-study-of-baricitinib-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-biological-agents-ra-beacon
#16
RANDOMIZED CONTROLLED TRIAL
Josef S Smolen, Joel M Kremer, Carol L Gaich, Amy M DeLozier, Douglas E Schlichting, Li Xie, Ivaylo Stoykov, Terence Rooney, Paul Bird, Juan Miguel Sánchez Bursón, Mark C Genovese, Bernard Combe
OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs). METHODS: In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis...
April 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27659057/rheumatoid-arthritis-patients-with-fibromyalgic-clinical-features-have-significantly-less-synovitis-as-defined-by-power-doppler-ultrasound
#17
Aneela N Mian, Khaldoun Chaabo, Julekha Wajed, Sujith Subesinghe, Nicola J Gullick, Bruce Kirkham, Toby Garrood
BACKGROUND: In patients with rheumatoid arthritis (RA) clinical measures of disease activity may not reliably discriminate between patients with active inflammatory disease and those with concomitant fibromyalgia (FM). Recent work has shown RA patients with a 28 tender joint count (TJC) minus swollen joint count (SJC) of 7 or more (joint count criteria) are more likely to meet classification criteria for FM. This study aimed to determine whether RA patients meeting clinical criteria for FM had lower levels of joint inflammation as determined by ultrasound (US)...
September 23, 2016: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27689735/baricitinib-in-patients-with-inadequate-response-or-intolerance-to-conventional-synthetic-dmards-results-from-the-ra-build-study
#18
RANDOMIZED CONTROLLED TRIAL
Maxime Dougados, Désirée van der Heijde, Ying-Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott Beattie, Sarah Witt, Inmaculada de la Torre, Carol Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery
BACKGROUND: Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS: In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3...
January 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27495156/impact-of-disease-activity-and-treatment-of-comorbidities-on-the-risk-of-myocardial-infarction-in-rheumatoid-arthritis
#19
Yvette Meissner, Angela Zink, Jörn Kekow, Karin Rockwitz, Anke Liebhaber, Silke Zinke, Kerstin Gerhold, Adrian Richter, Joachim Listing, Anja Strangfeld
BACKGROUND: The aim was to estimate the impact of individual risk factors and treatment with various disease-modifying antirheumatic drugs (DMARDs) on the incidence of myocardial infarction (MI) in patients with rheumatoid arthritis (RA). METHODS: We analysed data from 11,285 patients with RA, enrolled in the prospective cohort study RABBIT, at the start of biologic (b) or conventional synthetic (cs) DMARDs. A nested case-control study was conducted, defining patients with MI during follow-up as cases...
August 5, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27546493/self-limiting-arthritis-among-patients-fulfilling-the-2010-acr-eular-classification-criteria-for-rheumatoid-arthritis-in-a-very-early-arthritis-cohort
#20
Ellen Sauar Norli, Gina H Brinkmann, Tore K Kvien, Olav Bjørneboe, Anne J Haugen, Halvor Nygaard, Cathrine Thunem, Elisabeth Lie, Maria D Mjaavatten
OBJECTIVES: To study occurrence of and factors associated with self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) (2010 RA criteria) in patients with ≤16 weeks׳ duration of joint swelling. METHODS: We applied the 2010 RA criteria in 1118 patients included in a 2-year longitudinal cohort. In all, 256 patients fulfilled the 2010 RA criteria at baseline; outcome was defined as either "self-limiting arthritis" (no DMARD use during follow-up, no swollen joints at last assessment, and no final clinical diagnosis of RA) or "persistent disease...
December 2016: Seminars in Arthritis and Rheumatism
label_collection
label_collection
5160
1
2
2016-09-23 23:28:08
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"